Literature DB >> 24488561

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Juan-Carlos Hernández-Boluda1, Arturo Pereira, Montse Gómez, Concepción Boqué, Francisca Ferrer-Marín, José-María Raya, Valentín García-Gutiérrez, Ana Kerguelen, Blanca Xicoy, Pere Barba, Jesús Martínez, Elisa Luño, Alberto Alvarez-Larrán, Joaquín Martínez-López, Elisa Arbelo, Carles Besses.   

Abstract

Entities:  

Keywords:  IPSS; post-ET myelofibrosis; post-PV myelofibrosis; prognostic factors; survival

Mesh：

Year:  2014        PMID： 24488561      PMCID： PMC3971095          DOI： 10.3324/haematol.2013.101733

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Authors:  Francesco Passamonti; Elisa Rumi; Marianna Caramella; Chiara Elena; Luca Arcaini; Emanuela Boveri; Cecilia Del Curto; Daniela Pietra; Laura Vanelli; Paolo Bernasconi; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

2.  JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Authors:  Paola Guglielmelli; Giovanni Barosi; Lisa Pieri; Elisabetta Antonioli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2008-11-27       Impact factor: 9.941

3.  Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.

Authors:  Alberto Alvarez-Larrán; Beatriz Bellosillo; Luz Martínez-Avilés; Silvia Saumell; Antonio Salar; Eugenia Abella; Eva Gimeno; Sergi Serrano; Lourdes Florensa; Blanca Sánchez; Carmen Pedro; Carles Besses
Journal:  Br J Haematol       Date:  2009-07-08       Impact factor: 6.998

4.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

5.  Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Authors:  David Dingli; Susan M Schwager; Ruben A Mesa; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

6.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

7.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

8.  Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Alice Lynn; Sherry Pierce; Lingsha Zhou; Michael J Keating; Deborah A Thomas; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

9.  Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.

Authors:  Francisco Cervantes; Alberto Alvarez-Larrán; Carme Talarn; Marta Gómez; Emilio Montserrat
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

10.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Authors:  D Caramazza; K H Begna; N Gangat; R Vaidya; S Siragusa; D L Van Dyke; C Hanson; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528
View more
  20 in total

1.  Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Authors:  F Passamonti; B Mora; T Giorgino; P Guglielmelli; M Cazzola; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R Silver; G Benevolo; F Albano; D Caramazza; E Rumi; M Merli; D Pietra; R Casalone; T Barbui; L Pieri; A M Vannucchi
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

Review 2.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

5.  Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

Authors:  J-C Hernández-Boluda; A Pereira; J-G Correa; A Alvarez-Larrán; F Ferrer-Marín; J-M Raya; J Martínez-López; M Pérez-Encinas; N Estrada; P Velez; M-L Fox; V García-Gutiérrez; A Payer; A Kerguelen; B Cuevas; M-A Durán; M-J Ramírez; M-T Gómez-Casares; M-I Mata-Vázquez; E Mora; C Martínez-Valverde; M Gómez; F Cervantes
Journal:  Leukemia       Date:  2017-09-22       Impact factor: 11.528

6.  Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.

Authors:  K Gowin; S Verstovsek; N Daver; N Pemmaraju; R Valdez; H Kosiorek; A Dueck; R Mesa
Journal:  Leuk Res       Date:  2015-04-17       Impact factor: 3.156

Review 7.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 8.  Mutational profiling in myelofibrosis: implications for management.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2019-10-19       Impact factor: 2.490

9.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  Lucia Masarova; Ahmad Alhuraiji; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2018-01-17       Impact factor: 2.997

Review 10.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.